<DOC>
	<DOCNO>NCT03074344</DOCNO>
	<brief_summary>Background : Dry eye disease ( DED ) common condition cause burden visual function reduce quality life . Corticosteroids and/or cyclosporine eye drop able improve DED symptom , however , side effect immune suppression cost lead patient often suspend treatment . Consequently , important identify therapy alleviate DED symptom . A randomized , control , single mask study , perform 40 patient affected mild moderate DED , evaluate efficacy safety collyrium base cross-linked hyaluronic acid ( XLHA ) add Coenzyme Q10 ( CoQ10 ) comparison eye drop consider gold standard tear substitute , base hyaluronic acid ( HA ) 0.15 % . Methods : eye drop administer four time day 90 day enrol subject divide two group : group A treat XLHA+CoQ10 , group B treat HA . Ocular Surface Disease Index ( OSDI ) questionnaire , visual acuity , intraocular pressure ( IOP ) , fundus exam , tear break-up time ( TBUT ) , corneal conjunctival fluorescein staining , corneal esthesiometry , corneal confocal microscopy , perform different visit 90th day .</brief_summary>
	<brief_title>Cross-linked Hyaluronic Acid Coenzyme Q10 Treatment Dry Eye</brief_title>
	<detailed_description>Introduction : Dry eye disease ( DED ) common eye condition cause burden visual function reduce quality life work productivity . DED tear film disorder result hyperosmolarity tear film inflammation ocular surface result symptoms discomfort , visual disturbance , tear film instability potential damage ocular surface . This condition provoke traumatisms cause movement eyelid ocular surface insufficient cleanse microbial agent and/or foreign body . Prevalence DED increase age woman particularly susceptible , especially receive estrogen . The pathogenesis fully understand ; however , recognize inflammation prominent role . The common symptom DED : burning , foreign body sensation eye , difficulty open eyelid awaken , blur vision , severe case , pain photophobia . DED accompany increase tear film osmolarity inflammation ocular surface . There gold standard treatment DED , corticosteroid and/or cyclosporine eye drop improve symptom . However , give side effect immune suppression cost pharmaceutical preparation , patient often suspend treatment effectiveness therapy verify . Artificial tear consider mainstay dry eye treatment . Hyaluronic acid ( HA ) , natural glycosaminoglycan , component tear film . It increase tear film viscosity hydrate lubricate ocular surface . HA possess intrinsic water retention property , viscoelasticity favour heal corneal conjunctival epithelium . Safety efficacy HA treatment DED demonstrate . Eye-drops contain HA determine reduction ocular surface inflammation , consequent improvement quality corneal conjunctival epithelium . Our previous clinical study show HA beneficial effect conjunctival epithelium dry eye patient . Results another clinical trial , confirm beneficial effect HA show combination tamarind seed polysaccharide effective improve dry eye symptom , open new scenario treatment disease combine different molecule . Coenzyme Q10 ( CoQ10 ) endogenous , lipid soluble molecule , also know ubiquinone . CoQ10 play key role oxidative metabolism support adenosine triphosphate ( ATP ) mitochondrion , reduce form , act lipid antioxidant . In almost tissue human body , CoQ10 level decline age ocular function sensitive variation concentration CoQ10 . A randomized , control , single mask study , perform mild moderate dry eye patient , evaluate efficacy safety collyrium base cross-linked HA ( XLHA ) add CoQ10 comparison eye drop formulation , commonly use clinical practice consider gold standard tear substitute , treatment dry eye , base 0.15 % linear HA . Methods This randomise , single-masked , parallel-group comparative study investigate efficacy safety , treatment dry eye patient , ophthalmic solution contain XLHA add CoQ10 ( VisuXL® , Visufarma , Rome , Italy ) comparison formulation contain hyaluronic acid 0.15 % ( HA ) . The study screen 46 patient 40 enrolled [ ( 13 male , 17 female , age range 40-79 year ; mean age 62 ± 12.8 ( SD ) year ) ] suffer mild moderate dry eye attend Eye Clinic , Department Biomedical Sciences , Regional Referral Center Ocular Surface Diseases , University Messina , Messina , Italy . Enrolled subject divide two treatment group ( Group A receiving study formulation base XLHA+CoQ10 Group B receive comparator formulation base 0.15 % HA ) accord randomization scheme , correspond allocation code generate two treatment use permuted block method . The two eye-drops composition use study follow : group A formulation ( XLHA+CoQ10 ) : 100 ml contain Cross-Linked HA sodium salt 100 mg , Coenzyme Q10 100 mg , Vitamin E tocopheryl polyethylene glycol succinate ( TPGS ) 500 mg ( solubilizing agent lipid soluble CoQ10 ) , Isotonic buffer solution q.s . 100 ml ; group B formulation : HA sodium salt 100 mg ; isotonic buffer solution q.s . 100 ml . Both formulation unpreserved . All patient include treated run-in period 7 day one eye drop saline four time daily . At end period ( time 0 study ) subject randomly divide two group assign treatment . The visit carry blind fashion investigator . Eye drop administer four time day 12 week subject enrol study underwent grade subjective symptom clinical examination time 0 15 , 30 , 90 day . The patient allow know brand name eye drop use . Outcomes The Ocular Surface Disease Index ( OSDI ) questionnaire , visual acuity , intraocular pressure ( IOP ) , fundus exam , tear break-up time ( TBUT ) , corneal conjunctival fluorescein staining , esthesiometry , corneal confocal microscopy . Adverse event monitor . OSDI one widely use questionnaire . The 12-item OSDI questionnaire score range 0 100 , high score represent high disability . The scale show good sensitivity discriminate normal people subject affect dry eye correlate well disease severity . The ocular surface fluorescein stain score assess 3 minute instillation fluorescein ; modify Oxford score use : cornea conjunctiva score separately 0 5 ( 0 = none 5 = extend area confluent stain ) , conjunctiva mean score nasal temporal region use . The ocular surface observe cobalt blue light Wratten # 12 yellow filter.The difference among score obtain visit calculate . Corneal sensitivity measure Cochet-Bonnet aesthesiometer evaluate activity ophthalmic branch fifth cranial nerve ( trigeminal ) . It measure evaluate length filament able evoke tactile sensation ( mm filament ) . In vivo confocal microscopy perform , topical instillation drop unpreserved 0.4 % oxybuprocaine , use 40x contact objective additional Z-Ring probe , allow precise position probe central corneal area . For statistical analysis , result right eye consider . Student 's t-test Mann-Whitney U-test use appropriate . Values P≤0.05 consider statistically significant .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>age 18 80 year , history least 3 month dry eye symptom referable mild moderate dry eye . presence ocular disease , present past , dry eye ; previous ocular surgery , use contact lens topic treatment tear substitute ; presence systemic disease require treatment systemic drug potentially interfere tear production ; hypersensitivity active substance excipients ; participation clinical trial 3 month prior begin study , pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dry Eye Syndrome</keyword>
	<keyword>artificial tear</keyword>
	<keyword>CoQ10</keyword>
	<keyword>Hyaluronic acid</keyword>
</DOC>